1931994-80-7

BAY1830839 is a novel potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC50 of 3 nM).

IRAK4-IN-20 (Compound BAY-1834845) is an orally active IRAK4 inhibitor with an IC50 of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research[1].

IRAK4: 3.55 nM (IC₅₀)

[1] Li Q, et al. Oral IRAK4 Inhibitor BAY-1834845 Prevents Acute Respiratory Distress Syndrome. Biomedicine & Pharmacotherapy, 2022: 113459.